Unknown

Dataset Information

0

Hope and Disappointment: Covalent Inhibitors to Overcome Drug Resistance in Non-Small Cell Lung Cancer.

ABSTRACT: In the last five years, the detailed understanding of how to overcome T790M drug resistance in non-small cell lung cancer (NSCLC) has culminated in the development of a third-generation of covalent EGFR inhibitors with excellent clinical outcomes. However, the emergence of a newly discovered acquired drug resistance challenges the concept of small molecule targeted cancer therapy in NSCLC.

SUBMITTER: Engel J 

PROVIDER: S-EPMC4716607 | biostudies-literature | 2016 Jan

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Hope and Disappointment: Covalent Inhibitors to Overcome Drug Resistance in Non-Small Cell Lung Cancer.

Engel Julian J   Lategahn Jonas J   Rauh Daniel D  

ACS medicinal chemistry letters 20151218 1

In the last five years, the detailed understanding of how to overcome T790M drug resistance in non-small cell lung cancer (NSCLC) has culminated in the development of a third-generation of covalent EGFR inhibitors with excellent clinical outcomes. However, the emergence of a newly discovered acquired drug resistance challenges the concept of small molecule targeted cancer therapy in NSCLC. ...[more]

Similar Datasets

Unknown Medicinal herbs and bioactive compounds overcome the drug resistance to epidermal growth factor receptor inhibitors in non-small cell lung cancer.
| S-EPMC8299012 | biostudies-literature
Unknown Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer.
| S-EPMC5528378 | biostudies-literature
Unknown Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancer.
| S-EPMC3230244 | biostudies-literature
Unknown Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors.
| S-EPMC4234547 | biostudies-literature
Unknown Strategies to overcome drug resistance using SHP2 inhibitors.
| S-EPMC8727779 | biostudies-literature
Unknown Targeting the Golgi apparatus to overcome acquired resistance of non-small cell lung cancer cells to EGFR tyrosine kinase inhibitors.
| S-EPMC5788588 | biostudies-literature
Unknown Current Knowledge about Mechanisms of Drug Resistance against ALK Inhibitors in Non-Small Cell Lung Cancer.
| S-EPMC7915291 | biostudies-literature
Unknown Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors.
| S-EPMC4855947 | biostudies-literature
Unknown Novel HDAC11 inhibitors suppress lung adenocarcinoma stem cell self-renewal and overcome drug resistance by suppressing Sox2.
| S-EPMC7069992 | biostudies-literature
Unknown Histone Deacetylase Inhibition in Non-small Cell Lung Cancer: Hype or Hope?
| S-EPMC7581936 | biostudies-literature